Adjuvant Treatment of Melanoma

Table 6

Melanomas. Adjuvant treatment with nonspecific immune stimulants. Randomised studies [20].

Authors	No. of cases	Stage	Treatment	Followup (years)	Statistical significance
Balch 1982	260	III	C. parvum	2 y.	NS
Paterson 1984	199	I-II	BCG	4 y.	NS
Miller 1988	168	II-III	Transfer factor	2 y.	NS
			Observation
Lipton 1991	262		C. parvum	4–9 y.	CS
			BCG
Quirt 1991	577	I-IIA-IIB	Levamisole
			BCG
			BCG + Levamisole
			Observation
Spitler 1991	216	I-IIA-IIB-III-IV	Levamisole	10 y.	NS
			Observation
Czarnetzki 1993	353	II	BCG (RIV)	6 y.	NS
			BCG (Pasteur)
			Observation

CS: close to significance. NS: not significant.